North-Western register of patients with inflammatory bowel diseases: achievements and lessons learned

The problem of inflammatory bowel disease (IBD) — ulcerative colitis (UC) and Crohn's disease (CD) has not lost its urgency for several decades. Patients with IBD require long-term, continuous, often lifelong therapy and follow-up. This paper presents the data of patients’ register, worked outin Mechnikov North-Western State Medical University, in the Centre of IBD treatment.
As per the Register, an average time of diagnosis was 2.6 years (30.7 months) — for CD and 1.1 year (12.7 months) — for UC. At the same time, only 36.9% of CD patients versus 72% of UC patients were diagnosed within the first year, with the peak incidence at the age between 18 and 30 years.
Extra-intestinal manifestations are marked in 43.5% of CD patients and in 23.2% of UC patients. Besides, a quarter of them have more than one extra-intestinal symptoms, with bone and joint involvement domination (in 29.2% of CD patients and 18.4% of UC patients).
Epidemiological registers, including IBD registers, form an important database on the incidence, characteristics, regional distribution, and nature of the disease development, which helps to navigate the profile of patients, investigate possible causes and determine risk factors affecting its course.
However, the unified Federal Register will allow us to get a complete picture of patients with IBD in the country.
In addition, maintaining a national register and pharmaco-economical evaluation of various treatment methods will, in our opinion, optimize treatment costs; ensure rational planning and use of budgetary funds.

1. Maev I.V., Shelygin Yu.A., Skalinskaya M.I. et al. Pathomorphosis of inflammatory bowel diseases. Bulletin of the Russian Academy of Medical Sciences. 2020; 75(1):27-35. DOI:10.15690/vramn1219. ( in Russ.).

2. Veselov A.V. Analiz dannykh meditsinskoi statistiki po voprosam okazaniya koloproktologicheskoi pomoshchi naseleniyu goroda Moskvy. Klinicheskii opyt Dvadtsatki. 2014. - №4(24). – S.26-29 ( in Russ.).

3. Binnatli Sh.A., Aleshin D.V., Kulikov A.E. et al. Binnatli Sh.A., Aleshin D.V., Kulikov A.E. i dr. Kachestvo zhizni patsientov, operirovannykh po povodu yazvennogo kolita (obzor literatury). Koloproktologia. 2019;18(1):89-100. (in Russ.).

4. Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2018;390(10114): 2769-2778. DOI:10.1016/S0140-6736(17)32448-0

5. Ghersin I, Khteeb N, Katz LH et al. Trends in the epidemiology of inflammatory bowel disease among Jewish Israeli adolescents: a population-based study. Alimentary Pharmacology and Therapiutics. 2019; 49(5): 556-563. DOI:10.1111/apt.15160.

6. Park SH, Kim YJ, Rhee KH et al. A 30-year trend analysis in the epidemiology of inflammatory bowel disease in the Songpa-Kangdong District of Seoul, Korea in 1986-2015. Journal of Crohn's and Colitis. 2019; jjz081. DOI:10.1093/ecco-jcc/jjz081

7. Bernstein CN, Nugent Z, Targownik LE et al. Predictors and risks for death in a population-based study of persons with IBD in Manitoba. Gut. 2015 Sep; 64(9):1403-11. DOI:10.1136/gutjnl-2014-307983.

8. Lutgens MW, van Oijen MG, van der Heijden GJ et al. Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflammatory Bowel Disease. 2013 Mar-Apr; 19(4):789-99. DOI:10.1097/MIB.0b013e31828029c0.

9. Ivashkin V.T., Shelygin Yu.A., et al. Klinicheskie rekomendatsii rossiiskoi gastroenterologicheskoi assotsiatsii i assotsiatsii koloproktologov Rossii po diagnostike i lecheniyu yazvennogo kolita. Koloproktologia. 2017;1: 6-30. ( in Russ.).

10. Ivashkin V.T., Shelygin Yu.A., Abdulganieva D.I. et al. Crohn's disease. Сlinical recommendations (Preliminary version). Koloproktologia. 2020; 19(2):8-38. (in Russ.). https://doi.org/10.33878/2073-7556-2020-19-2-8-38

11. Burisch J, Katsanos KH, Christodoulou DK et al. Natural Disease Course of Ulcerative Colitis During the First Five Years of Follow-up in a European Population-based Inception Cohort-An Epi-IBD Study. Journal of Crohn's and Colitis. 2019 Feb 1; 13(2):198-208. DOI:10.1093/ecco-jcc/jjy154.

12. Kashnikov V.N. Khirurgicheskaya strategiya lecheniya bol'nykh yazvennym kolitom. Dis. … d-ra. med. nauk. Moskva; 2017. (in Russ.).

13. Angelo Viscido, Claudio Papi, Giovanni Latella et al. Has infliximab influenced the course and prognosis of acute severe ulcerative colitis? Biologics. 2019 Apr 9; 13: 23–31. DOI:10.2147/BTT.S179006.

14. Candido FD, Fiorino G, Spadaccini M, et al. Are Surgical Rates Decreasing in the Biological Era In IBD?. Current drug targets. 2019;20(13): 1356-1362. DOI:10.2174/1389450120666190426165325.

15. Last JM. A Dictionary of Epidemiology. In: Last JM, Harris SS. (Hrsg.) New York: New York Oxford University Press; 2000.

16. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med. 2000; 342: 1878-1886.

17. Van Vollenhoven RF, Askling J. Rheumatoid arthritis registries in Sweden. Clin Exp Rheumatol. 2005;23(5 Suppl 39):S195–200.

18. Gordon H, Langholz E. The EpiCom Survey-Registries Across Europe, Epidemiological Research and Beyond. J Crohns Colitis. 2017 Aug 1;11(8):1019-1021. DOI:10.1093/ecco-jcc/jjx013. PMID:28158624.

19. Simian D, Fluxá D, Flores L, Lubascher J, et al. Inflammatory bowel disease: A descriptive study of 716 local Chilean patients. World J Gastroenterol. 2016 June 14, 22 (22), С. 5267-5275.;

20. Bakulin I.G., Zhigalova T.N., Latariya E.L., et al. Experience of introduction of the Federal Registry of patients with inflammatory bowel diseases in Saint Petersburg. Farmateka. 2017; S5: 56-59. (in Russ.).

21. Osipenko M.F., Valuiskikh E.Yu., Svetlova I.O. et al Register of inflammatory bowel diseases in Novosibirsk – 2016. Sibirskii nauchnyi meditsinskii zhurnal. 2017; 37(1):61-67. (in Russ.).

22. Bakulin I.G., Shkurko T.V., Parfenov A.I., Knyazev O.V., et al. On the issue of the prevalence and incidence of inflammatory bowel diseases in Moscow. Pharmateca. 2016;2 (315): 69-73. (in Russ.).

23. Abdulganieva D.I., Bodryagina E.S., Odintsova A.Kh. Clinical and epidemiological indicators of inflammatory bowel diseases in the Republic of Tatarstan. Lechashchiy vrach. 2013; 7:21-26. (in Russ.).

24. Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol. 2001;96(4):1116-1122. DOI:10.1111/j.1572-0241.2001.03756

25. Walldorf J, Twarz M, Schober C, Michl P, Hammer T. High frequency of secondary, but not primary ocular manifestations of inflammatory bowel disease in patients treated at a tertiary care center. Eur J Gastroenterol Hepatol. 2018;30(12):1502-1506. doi:10.1097/MEG.0000000000001248

26. Karmiris K, Avgerinos A, Tavernaraki A, et al. Prevalence and Characteristics of Extra-intestinal Manifestations in a Large Cohort of Greek Patients with Inflammatory Bowel Disease. J Crohns Colitis. 2016;10(4):429-436. DOI:10.1093/ecco-jcc/jjv232

27. Vavricka SR, Rogler G, Gantenbein C, et al. Chronological Order of Appearance of Extraintestinal Manifestations Relative to the Time of IBD Diagnosis in the Swiss Inflammatory Bowel Disease Cohort. Inflamm Bowel Dis. 2015;21(8):1794-1800. DOI:10.1097/MIB.0000000000000429

28. Roth N, Biedermann L, Fournier N, et al. Occurrence of skin manifestations in patients of the Swiss Inflammatory Bowel Disease Cohort Study. PLOS ONE. 2019;14(1):e0210436. DOI:10.1371/journal.pone.0210436;

29. van Erp SJ, Brakenhoff LK, van Gaalen FA, et al. Classifying Back Pain and Peripheral Joint Complaints in Inflammatory Bowel Disease Patients: A Prospective Longitudinal Follow-up Study. J Crohns Colitis. 2016;10(2):166-175. DOI:10.1093/ecco-jcc/jjv195

30. Severs M, Spekhorst LM, Mangen MJJ, et al. Sex-Related Differences in Patients With Inflammatory Bowel Disease: Results of 2 Prospective Cohort Studies. Inflamm Bowel Dis. 2018;24(6):1298-1306. DOI:10.1093/ibd/izy004;

31. Roberts H, Rai SN, Pan J, et al. Extraintestinal manifestations of inflammatory bowel disease and the influence of smoking. Digestion. 2014;90(2):122-129. DOI:10.1159/000363228

32. Bakulin I.G., Skalinskaya M.I., Mayev I.V. i soavt. Farmakoterapiya vospalitel'nykh zabolevaniy kishechnika: upravleniye effektivnost'yu i bezopasnost'yu. Terapevticheskiy arkhiv. 2021; 93(8):841-852. (in Russ.). DOI:10.26442/00403660.2021.08.200982

33. Ye Y, Pang Z, Chen W, Ju S, Zhou C. The epidemiology and risk factors of inflammatory bowel disease. Int J Clin Exp Med. 2015, 8 (12). С. 22529-22542.

34. Regional'nyy registr po bolezni Krona kak instrument prospektivnogo nablyudeniya za patsiyentami. Prakticheskaya meditsina. 2014; 1(4):17-19. (in Russ.).